An observational study in Diabetes Mellitus, Type 2, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Chong Kun Dang Pharmaceutical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Chong Kun Dang Pharmaceutical.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is one of 8 that started in 2024, is one of 2 observational ones, and was the 55th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical
Ages 19–54 · Healthy volunteers
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 300 across 1,744 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 30 across the 62 interventional studies, 6,114 across the 2 observational. Of the 45 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365358Chong Kun Dang PharmaceuticalEvaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.
Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.
The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.
Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs.
Drug: SGLT2 inhibitor · Drug: DPP-4 inhibitor
Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs.
Drug: Thiazolidinedione · Drug: DPP-4 inhibitor
Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs.
Drug: SGLT2 inhibitor · Drug: DPP-4 inhibitor
Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs.
Drug: SGLT2 inhibitor · Drug: Thiazolidinedione
SGLT2 inhibitor class of drugs
Thiazolidinedione class of drugs
DPP4 inhibitor class of drugs
Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin
Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period.
Time frame: Up to 24 months
Changes in HbA1c
Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group
Time frame: 3, 6, (9), 12, 18, and 24 months
Changes in FPG
Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group
Time frame: 3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 7.0%
Percentage of Subjects with HbA1c \< 7.0% in Each Combination Group
Time frame: 3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 6.5%
Percentage of Subjects with HbA1c \< 6.5% in Each Combination Group
Time frame: 3, 6, (9), 12, 18, and 24 months
Factors influencing HbA1c change at each time point in each combination group.
demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc.
Time frame: 3, 6, (9), 12, 18, and 24 months
Changes in Weight
Changes in Weight(kg) Compared to Baseline in Each Combination Group
Time frame: 3, 6, (9), 12, 18, 24 months
Changes in waist circumference
Changes in waist circumference(cm) compared to Baseline in Each Combination Group
Time frame: 12 and 24 months
Changes in body composition(protein mass)
Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.
Time frame: 12 and 24 months
Changes in body composition(protein mass)
Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.
Time frame: 12 and 24 months
Changes in body composition(body fat)
Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model.
Time frame: 12 and 24 months
Changes in body composition(mineral mass)
Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model.
Time frame: 12 and 24 months
Changes in Fatty Liver Index
Changes in Fatty Liver Index compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes in AST
Changes in AST(IU/L) Compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes in ALT
Changes in ALT(IU/L) Compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes Platelet Levels
Changes in Platelet(10\^3/uL) Levels Compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)
Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes in Insulin-Related Test Levels(HOMA-IR)
Changes in HOMA-IR compared to Baseline in Each Combination Group
Time frame: 12 and 24 months
Changes in Insulin-Related Test Levels(HOMA-β)
Changes in HOMA-β(%) compared to Baseline in Each Combination Group
Time frame: 12 and 24 months
Changes in eGFR
Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Changes in UACR
Changes in UACR(mg/g) compared to Baseline in Each Combination Group
Time frame: 6, 12, 18, and 24 months
Change in hsCRP
Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group
Time frame: 12 and 24 months
Change in ProBNP(or NT-ProBNP)
Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group
Time frame: 12 and 24 months
Change in PP2 Compared to Baseline in Each Combination Group
Change in PP2(mg/dL) compared to Baseline in Each Combination Group.
Time frame: 3, 6, (9), 12, 18, and 24 months
Incidence Rate of Major Adverse Cardiovascular Events(MACE)
Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group
Time frame: 24 month
Incidence Rate of Diabetic Microvascular Events
Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group
Time frame: 24 month
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Oct 2028, 57 months after the start.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 57 months is above that.
Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Mar 2024 → Jan 2024 and primary completion Dec 2026 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →